| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cyclophosphamide | 83 | 2023 | 3080 | 10.690 |
Why?
|
| Graft vs Host Disease | 97 | 2023 | 2734 | 10.090 |
Why?
|
| Bone Marrow Transplantation | 58 | 2023 | 1638 | 8.160 |
Why?
|
| Immunosuppressive Agents | 36 | 2022 | 1416 | 5.430 |
Why?
|
| Transplantation Conditioning | 49 | 2023 | 2286 | 4.670 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 52 | 2023 | 6606 | 4.440 |
Why?
|
| Transplantation, Haploidentical | 15 | 2020 | 140 | 4.090 |
Why?
|
| Hematologic Neoplasms | 30 | 2023 | 1901 | 3.280 |
Why?
|
| HLA Antigens | 22 | 2020 | 563 | 2.850 |
Why?
|
| Transplantation, Homologous | 47 | 2023 | 2892 | 2.700 |
Why?
|
| Tissue Donors | 20 | 2023 | 789 | 1.980 |
Why?
|
| Unrelated Donors | 15 | 2023 | 319 | 1.900 |
Why?
|
| Histocompatibility Testing | 21 | 2020 | 467 | 1.620 |
Why?
|
| Leukemia, Myeloid, Acute | 19 | 2022 | 6932 | 1.370 |
Why?
|
| Antilymphocyte Serum | 3 | 2019 | 230 | 1.280 |
Why?
|
| T-Lymphocytes, Regulatory | 6 | 2016 | 674 | 1.220 |
Why?
|
| Tacrolimus | 5 | 2021 | 342 | 1.110 |
Why?
|
| Haplotypes | 8 | 2016 | 866 | 1.050 |
Why?
|
| Histocompatibility | 13 | 2020 | 182 | 1.050 |
Why?
|
| Myeloablative Agonists | 5 | 2021 | 389 | 1.010 |
Why?
|
| Major Histocompatibility Complex | 3 | 2017 | 94 | 1.000 |
Why?
|
| Antineoplastic Agents, Alkylating | 8 | 2017 | 591 | 1.000 |
Why?
|
| T-Lymphocytes | 17 | 2023 | 3878 | 0.970 |
Why?
|
| Allografts | 11 | 2018 | 656 | 0.920 |
Why?
|
| Stem Cell Transplantation | 7 | 2017 | 1367 | 0.900 |
Why?
|
| Immune Reconstitution | 2 | 2022 | 24 | 0.880 |
Why?
|
| Immune System Diseases | 1 | 2022 | 66 | 0.830 |
Why?
|
| B-Lymphocytes | 8 | 2022 | 1306 | 0.820 |
Why?
|
| Calcineurin Inhibitors | 1 | 2021 | 69 | 0.790 |
Why?
|
| Ursidae | 1 | 2020 | 3 | 0.770 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2023 | 2781 | 0.760 |
Why?
|
| Chimerism | 2 | 2019 | 65 | 0.720 |
Why?
|
| Humans | 133 | 2023 | 261892 | 0.710 |
Why?
|
| Killer Cells, Natural | 3 | 2022 | 907 | 0.700 |
Why?
|
| Recurrence | 20 | 2023 | 4783 | 0.700 |
Why?
|
| Immune Tolerance | 3 | 2023 | 405 | 0.680 |
Why?
|
| Lymphoma | 6 | 2021 | 1471 | 0.680 |
Why?
|
| Bronchiolitis Obliterans | 7 | 2022 | 81 | 0.660 |
Why?
|
| Aldehyde Dehydrogenase | 2 | 2022 | 105 | 0.660 |
Why?
|
| Transplantation Chimera | 9 | 2016 | 163 | 0.640 |
Why?
|
| Methotrexate | 1 | 2021 | 1002 | 0.640 |
Why?
|
| Chronic Disease | 16 | 2022 | 1844 | 0.610 |
Why?
|
| Middle Aged | 65 | 2023 | 86444 | 0.590 |
Why?
|
| Whole-Body Irradiation | 6 | 2019 | 312 | 0.590 |
Why?
|
| Chemoprevention | 2 | 2016 | 244 | 0.570 |
Why?
|
| Lymphocyte Activation | 9 | 2019 | 1690 | 0.570 |
Why?
|
| Adult | 64 | 2023 | 78017 | 0.560 |
Why?
|
| Germinal Center | 4 | 2022 | 165 | 0.560 |
Why?
|
| Young Adult | 32 | 2023 | 21444 | 0.550 |
Why?
|
| Biomarkers | 4 | 2018 | 5052 | 0.540 |
Why?
|
| Immunomodulation | 3 | 2020 | 246 | 0.540 |
Why?
|
| Graft Survival | 7 | 2016 | 1071 | 0.540 |
Why?
|
| Anemia, Aplastic | 4 | 2023 | 218 | 0.530 |
Why?
|
| Male | 68 | 2022 | 123160 | 0.520 |
Why?
|
| Transplantation Tolerance | 2 | 2016 | 17 | 0.520 |
Why?
|
| Graft vs Host Reaction | 4 | 2008 | 63 | 0.510 |
Why?
|
| Graft vs Leukemia Effect | 3 | 2020 | 108 | 0.500 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2018 | 363 | 0.490 |
Why?
|
| Immunologic Factors | 3 | 2020 | 653 | 0.490 |
Why?
|
| Busulfan | 2 | 2015 | 766 | 0.480 |
Why?
|
| T-Lymphocyte Subsets | 7 | 2022 | 591 | 0.480 |
Why?
|
| Leukemia | 3 | 2021 | 1633 | 0.460 |
Why?
|
| Bone Marrow | 9 | 2022 | 2360 | 0.460 |
Why?
|
| Aged | 47 | 2021 | 70329 | 0.460 |
Why?
|
| Drug Monitoring | 1 | 2015 | 336 | 0.450 |
Why?
|
| Myelodysplastic Syndromes | 6 | 2021 | 2982 | 0.450 |
Why?
|
| Female | 69 | 2022 | 142100 | 0.450 |
Why?
|
| Acute Disease | 9 | 2022 | 2426 | 0.440 |
Why?
|
| Mice, Inbred BALB C | 11 | 2020 | 2344 | 0.430 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 939 | 0.430 |
Why?
|
| Lung Transplantation | 1 | 2016 | 369 | 0.420 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2019 | 831 | 0.410 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2019 | 219 | 0.400 |
Why?
|
| Haploidy | 3 | 2016 | 43 | 0.400 |
Why?
|
| Dendritic Cells | 2 | 2009 | 1088 | 0.390 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2022 | 1596 | 0.390 |
Why?
|
| Animals | 35 | 2022 | 59458 | 0.380 |
Why?
|
| Disease-Free Survival | 16 | 2021 | 10021 | 0.380 |
Why?
|
| Vidarabine | 6 | 2014 | 1347 | 0.380 |
Why?
|
| Lymphocyte Depletion | 5 | 2016 | 269 | 0.370 |
Why?
|
| Adolescent | 26 | 2023 | 31189 | 0.360 |
Why?
|
| Mice | 28 | 2022 | 34380 | 0.360 |
Why?
|
| Hypertension | 1 | 2019 | 1513 | 0.360 |
Why?
|
| Isoantibodies | 3 | 2018 | 115 | 0.350 |
Why?
|
| Leukemia, Myeloid | 1 | 2014 | 941 | 0.350 |
Why?
|
| Treatment Outcome | 29 | 2020 | 32980 | 0.330 |
Why?
|
| Scleroderma, Systemic | 1 | 2009 | 139 | 0.320 |
Why?
|
| Survival Analysis | 12 | 2019 | 9194 | 0.320 |
Why?
|
| Mice, Inbred C57BL | 14 | 2020 | 6924 | 0.320 |
Why?
|
| Immune System | 2 | 2009 | 282 | 0.320 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2008 | 32 | 0.320 |
Why?
|
| Lymphoma, B-Cell | 3 | 2015 | 897 | 0.310 |
Why?
|
| STAT3 Transcription Factor | 2 | 2016 | 1122 | 0.310 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2014 | 1040 | 0.300 |
Why?
|
| Cancer Vaccines | 2 | 2019 | 699 | 0.300 |
Why?
|
| Sirolimus | 2 | 2013 | 818 | 0.290 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2009 | 673 | 0.290 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 2 | 2022 | 183 | 0.290 |
Why?
|
| Time Factors | 9 | 2021 | 12952 | 0.290 |
Why?
|
| Langerhans Cells | 1 | 2006 | 51 | 0.280 |
Why?
|
| Neoplasms, Experimental | 1 | 2009 | 745 | 0.270 |
Why?
|
| Lymphocyte Transfusion | 3 | 2013 | 178 | 0.250 |
Why?
|
| Interleukin-10 | 1 | 2007 | 485 | 0.240 |
Why?
|
| Immunophenotyping | 5 | 2022 | 1684 | 0.240 |
Why?
|
| Graft Rejection | 5 | 2018 | 834 | 0.230 |
Why?
|
| Hodgkin Disease | 4 | 2020 | 1435 | 0.230 |
Why?
|
| Immunotherapy | 5 | 2022 | 3347 | 0.230 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2007 | 1041 | 0.220 |
Why?
|
| Disease Models, Animal | 10 | 2020 | 7216 | 0.220 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 4 | 2019 | 215 | 0.220 |
Why?
|
| Clinical Trials as Topic | 5 | 2018 | 3752 | 0.220 |
Why?
|
| Retrospective Studies | 19 | 2023 | 37994 | 0.220 |
Why?
|
| Proteomics | 2 | 2022 | 1385 | 0.210 |
Why?
|
| Remission Induction | 8 | 2020 | 3585 | 0.200 |
Why?
|
| Germany | 1 | 2021 | 112 | 0.200 |
Why?
|
| Lymphocyte Subsets | 1 | 2022 | 138 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 2 | 2018 | 127 | 0.200 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2013 | 89 | 0.190 |
Why?
|
| Prospective Studies | 10 | 2023 | 12878 | 0.190 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2022 | 1765 | 0.190 |
Why?
|
| Forkhead Transcription Factors | 2 | 2016 | 777 | 0.190 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2007 | 1236 | 0.190 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2022 | 248 | 0.190 |
Why?
|
| Child | 15 | 2023 | 29029 | 0.190 |
Why?
|
| Cyclosporine | 2 | 2014 | 282 | 0.180 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2022 | 184 | 0.180 |
Why?
|
| Leukemia, Experimental | 1 | 2020 | 78 | 0.180 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2020 | 71 | 0.170 |
Why?
|
| Receptors, CXCR5 | 2 | 2016 | 29 | 0.170 |
Why?
|
| Cytarabine | 3 | 2021 | 1976 | 0.170 |
Why?
|
| Machine Learning | 1 | 2022 | 322 | 0.170 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2022 | 295 | 0.170 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2020 | 130 | 0.170 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2015 | 749 | 0.170 |
Why?
|
| Hemoglobinopathies | 1 | 2019 | 25 | 0.170 |
Why?
|
| Donor Selection | 2 | 2019 | 109 | 0.170 |
Why?
|
| Postoperative Care | 2 | 2016 | 738 | 0.170 |
Why?
|
| Nephrocalcinosis | 1 | 2018 | 18 | 0.170 |
Why?
|
| Transplantation Immunology | 3 | 2016 | 99 | 0.170 |
Why?
|
| HIV-2 | 2 | 1995 | 12 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2016 | 6222 | 0.160 |
Why?
|
| HLA-DP beta-Chains | 1 | 2018 | 16 | 0.160 |
Why?
|
| Antineoplastic Agents | 6 | 2018 | 14286 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2019 | 173 | 0.160 |
Why?
|
| Telomere Homeostasis | 1 | 2018 | 74 | 0.160 |
Why?
|
| Neoplasm Grading | 3 | 2018 | 1750 | 0.160 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 83 | 0.160 |
Why?
|
| Leukocyte Common Antigens | 2 | 2015 | 186 | 0.150 |
Why?
|
| Hypercalcemia | 1 | 2018 | 139 | 0.150 |
Why?
|
| Skin Transplantation | 2 | 2013 | 177 | 0.150 |
Why?
|
| Siblings | 2 | 2019 | 289 | 0.150 |
Why?
|
| Pancreatitis-Associated Proteins | 1 | 2017 | 33 | 0.150 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 163 | 0.150 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2017 | 31 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 133 | 0.150 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2017 | 76 | 0.140 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 522 | 0.140 |
Why?
|
| Growth Disorders | 1 | 2018 | 219 | 0.140 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 171 | 0.140 |
Why?
|
| Gene Products, rev | 2 | 1996 | 10 | 0.140 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2017 | 165 | 0.140 |
Why?
|
| Consensus | 4 | 2023 | 1000 | 0.140 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2017 | 107 | 0.140 |
Why?
|
| Transcriptome | 2 | 2022 | 1863 | 0.140 |
Why?
|
| Thalidomide | 1 | 2020 | 570 | 0.140 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2018 | 240 | 0.140 |
Why?
|
| Dogs | 1 | 2018 | 1157 | 0.140 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 311 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 2323 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 3263 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2021 | 15874 | 0.130 |
Why?
|
| Postoperative Complications | 3 | 2020 | 5559 | 0.130 |
Why?
|
| Child, Preschool | 12 | 2023 | 16196 | 0.130 |
Why?
|
| Virus Replication | 3 | 1996 | 706 | 0.130 |
Why?
|
| rho-Associated Kinases | 1 | 2016 | 85 | 0.130 |
Why?
|
| Cytomegalovirus Infections | 2 | 2016 | 454 | 0.130 |
Why?
|
| Lymphocytes | 2 | 2019 | 1227 | 0.130 |
Why?
|
| Telomerase | 1 | 2018 | 524 | 0.130 |
Why?
|
| Gene Expression | 4 | 2018 | 3561 | 0.130 |
Why?
|
| Receptors, IgG | 1 | 2015 | 101 | 0.130 |
Why?
|
| Gene Products, tat | 1 | 1995 | 55 | 0.130 |
Why?
|
| Radioimmunotherapy | 1 | 2015 | 120 | 0.130 |
Why?
|
| Multiple Myeloma | 2 | 2017 | 2152 | 0.120 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2011 | 719 | 0.120 |
Why?
|
| Rituximab | 3 | 2015 | 1534 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 1054 | 0.120 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 14887 | 0.120 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 8881 | 0.120 |
Why?
|
| Pyridones | 1 | 2017 | 350 | 0.120 |
Why?
|
| Lymphoid Tissue | 1 | 2014 | 95 | 0.120 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 658 | 0.120 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 2860 | 0.120 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 447 | 0.120 |
Why?
|
| Primary Myelofibrosis | 1 | 2022 | 831 | 0.120 |
Why?
|
| Skin Diseases | 1 | 2017 | 351 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 4941 | 0.120 |
Why?
|
| Proteins | 1 | 2022 | 1951 | 0.120 |
Why?
|
| Antigens, CD34 | 1 | 2015 | 593 | 0.120 |
Why?
|
| Transplantation, Isogeneic | 3 | 2016 | 59 | 0.120 |
Why?
|
| Benzodiazepines | 1 | 1995 | 170 | 0.110 |
Why?
|
| HIV | 1 | 1995 | 229 | 0.110 |
Why?
|
| Ipilimumab | 1 | 2018 | 719 | 0.110 |
Why?
|
| Antibodies | 1 | 2017 | 833 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 596 | 0.110 |
Why?
|
| Survival Rate | 6 | 2018 | 12237 | 0.110 |
Why?
|
| Histiocytic Sarcoma | 1 | 2012 | 16 | 0.110 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2012 | 45 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 5 | 2016 | 4386 | 0.110 |
Why?
|
| Immunoconjugates | 1 | 2015 | 284 | 0.100 |
Why?
|
| Desensitization, Immunologic | 1 | 2013 | 97 | 0.100 |
Why?
|
| Mycophenolic Acid | 2 | 2012 | 149 | 0.100 |
Why?
|
| Mice, Knockout | 5 | 2020 | 5670 | 0.100 |
Why?
|
| Drug Administration Schedule | 4 | 2012 | 3480 | 0.100 |
Why?
|
| Flow Cytometry | 4 | 2015 | 3022 | 0.100 |
Why?
|
| Anemia, Sickle Cell | 2 | 2012 | 336 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 1108 | 0.100 |
Why?
|
| Trans-Activators | 1 | 2017 | 1557 | 0.100 |
Why?
|
| Incidence | 4 | 2017 | 5707 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2022 | 10066 | 0.100 |
Why?
|
| Monocytes | 1 | 1995 | 771 | 0.090 |
Why?
|
| Pyrroles | 1 | 1995 | 584 | 0.090 |
Why?
|
| Macrophages | 1 | 2017 | 1313 | 0.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2015 | 994 | 0.090 |
Why?
|
| Models, Animal | 2 | 2016 | 663 | 0.090 |
Why?
|
| Bayes Theorem | 1 | 2014 | 1033 | 0.090 |
Why?
|
| Salvage Therapy | 4 | 2012 | 2059 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 1094 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2008 | 2914 | 0.090 |
Why?
|
| Prognosis | 3 | 2022 | 21718 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 1540 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 1266 | 0.080 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2019 | 727 | 0.080 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2008 | 11 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 5154 | 0.080 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 1668 | 0.080 |
Why?
|
| DNA Methylation | 2 | 2018 | 2671 | 0.080 |
Why?
|
| Filgrastim | 1 | 2008 | 192 | 0.080 |
Why?
|
| Blood Component Transfusion | 1 | 2008 | 89 | 0.080 |
Why?
|
| HIV Infections | 1 | 2020 | 2136 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 259 | 0.080 |
Why?
|
| Infant | 7 | 2020 | 13269 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 1759 | 0.070 |
Why?
|
| United States | 2 | 2021 | 15554 | 0.070 |
Why?
|
| Graft vs Tumor Effect | 1 | 2007 | 140 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 2393 | 0.070 |
Why?
|
| Secondary Prevention | 3 | 2016 | 333 | 0.070 |
Why?
|
| Mice, Mutant Strains | 2 | 2019 | 623 | 0.070 |
Why?
|
| Aminoquinolines | 1 | 2006 | 47 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2020 | 2296 | 0.070 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 409 | 0.070 |
Why?
|
| Transplantation, Autologous | 2 | 2009 | 1925 | 0.070 |
Why?
|
| Immunologic Memory | 2 | 2019 | 374 | 0.070 |
Why?
|
| Antigens, Neoplasm | 2 | 2019 | 1505 | 0.070 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 518 | 0.070 |
Why?
|
| Transplants | 1 | 2006 | 53 | 0.070 |
Why?
|
| Risk Factors | 4 | 2017 | 17603 | 0.070 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 1516 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 3233 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2009 | 700 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2014 | 1479 | 0.070 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2011 | 802 | 0.070 |
Why?
|
| Living Donors | 1 | 2006 | 176 | 0.060 |
Why?
|
| Pyrimidines | 2 | 2015 | 3538 | 0.060 |
Why?
|
| Interleukin-2 | 3 | 2016 | 841 | 0.060 |
Why?
|
| Azacitidine | 1 | 2010 | 1149 | 0.060 |
Why?
|
| Apoptosis | 1 | 2018 | 7597 | 0.060 |
Why?
|
| Homeostasis | 1 | 2009 | 941 | 0.060 |
Why?
|
| Lymphocyte Count | 2 | 2017 | 488 | 0.060 |
Why?
|
| Etoposide | 2 | 2020 | 873 | 0.060 |
Why?
|
| Lymphoma, Follicular | 1 | 2009 | 591 | 0.060 |
Why?
|
| Cytokines | 3 | 2018 | 2823 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2016 | 506 | 0.060 |
Why?
|
| Myeloproliferative Disorders | 1 | 2010 | 769 | 0.060 |
Why?
|
| Pulmonary Fibrosis | 2 | 2017 | 172 | 0.060 |
Why?
|
| Biology | 1 | 2023 | 75 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 661 | 0.050 |
Why?
|
| Mutation | 2 | 2021 | 15167 | 0.050 |
Why?
|
| Risk | 2 | 2017 | 1972 | 0.050 |
Why?
|
| Mice, Inbred AKR | 1 | 2001 | 51 | 0.050 |
Why?
|
| Mice, Inbred DBA | 1 | 2001 | 109 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 8881 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 2022 | 1879 | 0.050 |
Why?
|
| Mice, Inbred C3H | 1 | 2001 | 380 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2015 | 1063 | 0.050 |
Why?
|
| Cell Separation | 2 | 2015 | 610 | 0.050 |
Why?
|
| Skin | 1 | 2006 | 1260 | 0.050 |
Why?
|
| Cell Count | 1 | 2002 | 506 | 0.050 |
Why?
|
| Medically Underserved Area | 1 | 2021 | 101 | 0.050 |
Why?
|
| HIV-1 | 2 | 1996 | 649 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 209 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 4768 | 0.050 |
Why?
|
| Alemtuzumab | 2 | 2012 | 198 | 0.050 |
Why?
|
| Disease Progression | 3 | 2016 | 6693 | 0.050 |
Why?
|
| Hexosamines | 1 | 2020 | 26 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 5374 | 0.040 |
Why?
|
| Transfection | 2 | 1995 | 2934 | 0.040 |
Why?
|
| Scleroderma, Localized | 1 | 2019 | 13 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 579 | 0.040 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 2 | 1996 | 16 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 5122 | 0.040 |
Why?
|
| Risk Assessment | 3 | 2017 | 6884 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 440 | 0.040 |
Why?
|
| Minority Groups | 1 | 2021 | 317 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2019 | 5594 | 0.040 |
Why?
|
| Receptors, OX40 | 1 | 2018 | 51 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 2016 | 1148 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 179 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 316 | 0.040 |
Why?
|
| Viral Load | 1 | 2020 | 492 | 0.040 |
Why?
|
| Immunoglobulin G | 2 | 2012 | 1030 | 0.040 |
Why?
|
| Syndrome | 2 | 2014 | 1350 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2011 | 869 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2021 | 483 | 0.040 |
Why?
|
| Safety | 1 | 2019 | 463 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2019 | 6128 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 249 | 0.040 |
Why?
|
| Piperidines | 2 | 2014 | 1053 | 0.040 |
Why?
|
| Patient Selection | 2 | 2015 | 2061 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2009 | 14557 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2012 | 1557 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2016 | 79 | 0.040 |
Why?
|
| Neoplasms | 3 | 2017 | 15178 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2018 | 669 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 5008 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 1290 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 665 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2001 | 1016 | 0.030 |
Why?
|
| San Francisco | 1 | 2016 | 21 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2016 | 38 | 0.030 |
Why?
|
| RNA, Catalytic | 1 | 1996 | 38 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2016 | 93 | 0.030 |
Why?
|
| Histocompatibility Antigen H-2D | 1 | 2015 | 6 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2019 | 322 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 196 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2007 | 4037 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2019 | 560 | 0.030 |
Why?
|
| Genes, rev | 1 | 1995 | 4 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2023 | 1162 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2006 | 2969 | 0.030 |
Why?
|
| Baltimore | 1 | 2015 | 29 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1995 | 260 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2018 | 464 | 0.030 |
Why?
|
| Syk Kinase | 1 | 2015 | 56 | 0.030 |
Why?
|
| Cell Nucleolus | 1 | 1995 | 90 | 0.030 |
Why?
|
| Drug Antagonism | 1 | 1995 | 33 | 0.030 |
Why?
|
| Defective Viruses | 1 | 1995 | 29 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2017 | 253 | 0.030 |
Why?
|
| Oxazines | 1 | 2015 | 44 | 0.030 |
Why?
|
| Weight Loss | 1 | 2019 | 630 | 0.030 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 1995 | 46 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 693 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2015 | 286 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2017 | 253 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1995 | 227 | 0.030 |
Why?
|
| Genome, Viral | 1 | 1995 | 155 | 0.030 |
Why?
|
| Receptors, Interleukin-21 | 1 | 2014 | 14 | 0.030 |
Why?
|
| Inducible T-Cell Co-Stimulator Ligand | 1 | 2014 | 21 | 0.030 |
Why?
|
| Karyotyping | 1 | 2016 | 1017 | 0.030 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2014 | 77 | 0.030 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2017 | 367 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2016 | 414 | 0.030 |
Why?
|
| Spleen | 1 | 2016 | 674 | 0.030 |
Why?
|
| CD40 Ligand | 1 | 2014 | 117 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2014 | 206 | 0.030 |
Why?
|
| ABO Blood-Group System | 1 | 2014 | 128 | 0.030 |
Why?
|
| CD40 Antigens | 1 | 2014 | 107 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 289 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 213 | 0.030 |
Why?
|
| RNA, Viral | 1 | 1996 | 667 | 0.030 |
Why?
|
| Fibrosis | 1 | 2016 | 767 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 2186 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 706 | 0.030 |
Why?
|
| Etanercept | 1 | 2012 | 65 | 0.030 |
Why?
|
| DNA Primers | 1 | 1995 | 1393 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2015 | 663 | 0.030 |
Why?
|
| Diphtheria Toxin | 1 | 2012 | 82 | 0.030 |
Why?
|
| Pentostatin | 1 | 2012 | 120 | 0.030 |
Why?
|
| Viral Proteins | 1 | 1995 | 437 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 190 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 2450 | 0.030 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2011 | 4 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2014 | 300 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2016 | 875 | 0.030 |
Why?
|
| Base Sequence | 2 | 1996 | 4881 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2013 | 180 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 662 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 796 | 0.030 |
Why?
|
| HeLa Cells | 1 | 1995 | 1642 | 0.030 |
Why?
|
| Interleukins | 1 | 2014 | 327 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2009 | 11969 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2011 | 166 | 0.020 |
Why?
|
| Adenine | 1 | 2014 | 639 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 6057 | 0.020 |
Why?
|
| Wound Healing | 1 | 2016 | 812 | 0.020 |
Why?
|
| Blood Donors | 1 | 2011 | 165 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 903 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 2233 | 0.020 |
Why?
|
| DNA Damage | 1 | 2018 | 1947 | 0.020 |
Why?
|
| Mitoxantrone | 1 | 2010 | 217 | 0.020 |
Why?
|
| Cell Line | 2 | 1996 | 5069 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2016 | 8202 | 0.020 |
Why?
|
| Aging | 1 | 2018 | 1533 | 0.020 |
Why?
|
| Cytosine | 1 | 2010 | 141 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2013 | 1316 | 0.020 |
Why?
|
| Daunorubicin | 1 | 2010 | 302 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 302 | 0.020 |
Why?
|
| Flavonoids | 1 | 2010 | 195 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 1995 | 3188 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 6020 | 0.020 |
Why?
|
| Fever | 1 | 2011 | 499 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2009 | 588 | 0.020 |
Why?
|
| Pyridines | 1 | 2015 | 1243 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 1382 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 5183 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1943 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 2146 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 3891 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 13669 | 0.020 |
Why?
|
| Neutropenia | 1 | 2011 | 965 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2009 | 561 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 2514 | 0.020 |
Why?
|
| Cause of Death | 1 | 2009 | 757 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2334 | 0.020 |
Why?
|
| Lung | 1 | 2016 | 3166 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4344 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 7239 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2011 | 942 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 4556 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 3632 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 4121 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 1267 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 4315 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2002 | 54 | 0.010 |
Why?
|
| Hospitalization | 1 | 2011 | 2110 | 0.010 |
Why?
|
| Pregnancy | 1 | 2009 | 7526 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 1207 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1996 | 675 | 0.010 |
Why?
|